ATE187964T1 - N-substituierte chinolinderivate, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen - Google Patents

N-substituierte chinolinderivate, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE187964T1
ATE187964T1 AT92400294T AT92400294T ATE187964T1 AT E187964 T1 ATE187964 T1 AT E187964T1 AT 92400294 T AT92400294 T AT 92400294T AT 92400294 T AT92400294 T AT 92400294T AT E187964 T1 ATE187964 T1 AT E187964T1
Authority
AT
Austria
Prior art keywords
production
pharmaceutical compositions
compositions containing
containing same
medicinal products
Prior art date
Application number
AT92400294T
Other languages
English (en)
Inventor
Francois Clemence
Michel Fortin
Jean-Luc Haesslein
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9101372A external-priority patent/FR2672597B1/fr
Priority claimed from FR9110433A external-priority patent/FR2680511B1/fr
Priority claimed from FR9114282A external-priority patent/FR2684671B1/fr
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Application granted granted Critical
Publication of ATE187964T1 publication Critical patent/ATE187964T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92400294T 1991-02-07 1992-02-05 N-substituierte chinolinderivate, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen ATE187964T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9101372A FR2672597B1 (fr) 1991-02-07 1991-02-07 Nouveaux derives n-substitues de la quinoleine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
FR9110433A FR2680511B1 (fr) 1991-08-20 1991-08-20 Derives n-substitues de la quinoleine, leur procede de preparation, intermediaires obtenus, leur application comme medicaments et les compositions les renfermant.
FR9114282A FR2684671B1 (fr) 1991-11-20 1991-11-20 Nouveaux derives de la quinoleine, leur procede de preparation et intermediaires et leur application a titre de medicaments.

Publications (1)

Publication Number Publication Date
ATE187964T1 true ATE187964T1 (de) 2000-01-15

Family

ID=27252397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92400294T ATE187964T1 (de) 1991-02-07 1992-02-05 N-substituierte chinolinderivate, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen

Country Status (24)

Country Link
US (1) US5985894A (de)
EP (1) EP0498721B1 (de)
JP (1) JP3599350B2 (de)
KR (1) KR100334208B1 (de)
CN (1) CN1064076A (de)
AT (1) ATE187964T1 (de)
BR (1) BR9200432A (de)
CA (1) CA2060843A1 (de)
CZ (1) CZ291217B6 (de)
DE (1) DE69230449T2 (de)
DK (1) DK0498721T3 (de)
ES (1) ES2141098T3 (de)
FI (1) FI103574B1 (de)
GR (1) GR3032711T3 (de)
HU (1) HUT64524A (de)
IE (1) IE920395A1 (de)
IL (1) IL100555A (de)
MA (1) MA22410A1 (de)
NZ (1) NZ241546A (de)
OA (1) OA09528A (de)
PL (1) PL169672B1 (de)
PT (1) PT498721E (de)
RU (1) RU2125047C1 (de)
TW (1) TW214554B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
GB9121727D0 (en) * 1991-10-14 1991-11-27 Ici Plc Heterocyclic compounds
JPH05310732A (ja) * 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
KR20030027094A (ko) * 2000-08-29 2003-04-03 야마노우치세이야쿠 가부시키가이샤 신규 에스테르 또는 아미드 유도체
EG24415A (en) * 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
US20040092427A1 (en) * 2002-09-25 2004-05-13 Anil Gulati Method and composition for treating alzheimer's disease and dementias of vascular origin
EP4059923A1 (de) 2002-11-20 2022-09-21 Japan Tobacco Inc. 4-oxochinolin-verbindung und verwendung davon als hiv-integrasehemmer
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP3287130A1 (de) 2004-05-21 2018-02-28 Japan Tobacco Inc. Kombinationen mit einem 4-isochinolon-derivat und proteaseinhibitoren
US20070071679A1 (en) * 2005-09-29 2007-03-29 Hilakivi Ilkka T Methylamine risks and treatment of hyperactivity, depression, and alcoholism with epinephrine-N-quinolines
EP2452682A1 (de) * 2006-02-01 2012-05-16 Japan Tobacco, Inc. Verwendung von 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-Carboxysäure oder einem Salz daraus zur Behandlung von einen Retrovireninfektion
AU2007223260C1 (en) 2006-03-06 2011-02-03 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (de) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
GB0716532D0 (en) * 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
TWI492943B (zh) * 2008-12-05 2015-07-21 大塚製藥股份有限公司 喹啉酮化合物及藥學組成物（二）
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3004138B1 (de) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2555943A (en) * 1947-06-28 1951-06-05 Sterling Drug Inc Dihalo-4-(aliphatic tertiaryamino-alkylamino)quinolines
US3002001A (en) * 1958-04-03 1961-09-26 Sterling Drug Inc 4-alkylimino-1-[aromatic-(lower - alkyl)]-1,4-dihydroquinolines and their preparation
GB1419788A (en) * 1972-08-02 1975-12-31 Pfizer Herbicidal method using 2-trifuluromethyl-4-quinolinols
GB1432649A (de) * 1973-09-07 1976-04-22 Ici Ltd
GB1472767A (en) * 1974-11-07 1977-05-04 Ici Ltd Process for the preparation of cinnoline derivatives
FR2377400A2 (fr) * 1977-01-18 1978-08-11 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
NZ193167A (en) * 1979-03-27 1984-08-24 Boots Co Plc Quinoline derivatives and pharmaceutical compositions
JPS58219166A (ja) * 1982-06-14 1983-12-20 Nippon Shinyaku Co Ltd ４−キノロン誘導体
US4920131A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US5081121A (en) * 1988-05-24 1992-01-14 Tatsushi Osawa 4(1h)-quinolone derivatives
US4918081A (en) * 1988-06-20 1990-04-17 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene d4
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
PT94960A (pt) * 1989-08-11 1991-04-18 Ici Plc Processo para a preparacao de derivados de quinolina e de composicoes farmaceuticas que as contem
CA2037630C (en) * 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US5157040A (en) * 1991-04-05 1992-10-20 Merck & Co., Inc. Substituted quinolines as angiotensin ii antagonists
US5162325A (en) * 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5162340A (en) * 1991-05-10 1992-11-10 Merck & Co., Inc. Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists

Also Published As

Publication number Publication date
RU2125047C1 (ru) 1999-01-20
PT498721E (pt) 2000-04-28
IL100555A0 (en) 1992-09-06
CN1064076A (zh) 1992-09-02
ES2141098T3 (es) 2000-03-16
IL100555A (en) 2000-08-31
PL293414A1 (en) 1993-05-04
CA2060843A1 (fr) 1992-08-08
EP0498721B1 (de) 1999-12-22
MA22410A1 (fr) 1992-10-01
EP0498721A1 (de) 1992-08-12
DE69230449T2 (de) 2000-08-03
OA09528A (fr) 1992-11-15
JPH04360872A (ja) 1992-12-14
TW214554B (de) 1993-10-11
CZ291217B6 (cs) 2003-01-15
DK0498721T3 (da) 2000-06-26
FI920504A0 (fi) 1992-02-06
FI920504A (fi) 1992-08-08
PL169672B1 (pl) 1996-08-30
FI103574B (fi) 1999-07-30
NZ241546A (en) 1995-03-28
KR100334208B1 (ko) 2002-08-09
DE69230449D1 (de) 2000-01-27
BR9200432A (pt) 1992-10-13
HUT64524A (en) 1994-01-28
FI103574B1 (fi) 1999-07-30
KR920016432A (ko) 1992-09-24
US5985894A (en) 1999-11-16
CZ35792A3 (en) 1993-10-13
GR3032711T3 (en) 2000-06-30
IE920395A1 (en) 1992-08-12
HU9200367D0 (en) 1992-04-28
JP3599350B2 (ja) 2004-12-08

Similar Documents

Publication Publication Date Title
ATE187964T1 (de) N-substituierte chinolinderivate, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
DE58907280D1 (de) 7-Substituierte Derivate der 3,5-Dihydroxyhept-6-insäure, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, sowie Zwischenprodukte.
ATE144503T1 (de) Thiazolidin-2,4-dionderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE205832T1 (de) Stickstoff enthaltende bicyclische verbindungen, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen
ATE217310T1 (de) Bicyclische pyridinderivate, verfahren zu ihrer herstellung, zwischenprodukte, ihre anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
DE69204662T2 (de) Poly-4-aminopyrrole-2-carboxamide derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE166344T1 (de) Schwefelderivate von imidazol, verfahren zu ihrer herstellung, zwischenprodukte, ihre verwendung als arzneimittel und sie enthaltende pharmazeutische zusammensetzungen
DE59000750D1 (de) Arzneimittel, enthaltend di-tert.-butylhydroxyphenyl-derivate sowie neue derivate.
NO945034L (no) Derivater i vitamin D-serien modifisert ved 20-stilling, en fremg. for frems. av slike derivater, mellomprodukter anvendt ved fremg., farmasöytiske preparater inneholdende derivatene og deres anvendelse ved frems. av legemidler
ATE62683T1 (de) Labdanderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel.
DE3869173D1 (de) Amino 5,6,7,8-tetrahydronaphtho(2,3b)furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE3782347D1 (de) Hetaryl-oxy-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel.
ATE150745T1 (de) 22-en-25-oxa-derivate in der vitamin d-reihe, verfahren zu ihrer herstellung, diese derivate enthaltenen pharmazeutische präparate sowie deren verwendung als arzneimittel
DK0564358T3 (da) 3-aminochroman-spiro-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende sådanne
ATE18221T1 (de) (1-arylcyclobutyl)(heterocyclyl)methylaminderivate, ihre herstellung und ihre verwendung als arzneimittel.
ATE128968T1 (de) 2-cyano-2-hydroxypropenamidederivate, verfahren zu ihrer herstellung ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen.
DE3678478D1 (de) Beta-lactam-antibiotika, verfahren zur herstellung und ihre verwendung als arzneimittel.
DE58907678D1 (de) 6-Fluor-3,5-dihydroxycarbonsäuren und deren Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, pharmazeutische Präparate und Zwischenprodukte.
ATE13669T1 (de) 4-aryloxy-3-phenylpiperidin-derivate, zwischenprodukte, verfahren zur herstellung solcher verbindungen und ihre verwendung als arzneimittel.
ATE189810T1 (de) Eine trifluormethylsulfonylphenyl- oder trifluormethylsulfinylphenylgruppe enthaltende 2- cyan-3-hydroxy-propenamidderivate, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
DE3879234D1 (de) Substituierte 3-phenyl-7h-thiazolo(3,2 -b) (1,2,4)triazin-7-one, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung, sowie einige bei der herstellung der genannten verbindungen gebildete zwischenprodukte.
DE69302279D1 (de) 3-und 5-substituierte 1,2,3,4,-oxatriazol-5-imin derivate, verfahren zu deren herstellung, diese enthaltende arzneimittel und verwendung dieser verbindungen zur herstellung von arzneimitteln
ATE146467T1 (de) Substituierte 3-azabicyclo(3.2.0>heptan-derivate als zwischenprodukte
DE59104473D1 (de) Arzneimittel welche substituierte 2-Cyclohexen-1yl-amin-Derivate enthalten und ihre Verwendung zur Bekämpfung von Krankheiten.
ATE74600T1 (de) Derivate von 5-(2-(1-pyrrolidinyl)-aethoxy>-pcymen, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee